Cardiology

Allegheny Health Network (AHN) Cardiovascular Institute is one of only a few centers offering intracoronary vascular brachytherapy, an innovative procedure providing hope for patients with challenging restenosis.

Allegheny Health Network (AHN) implants innovative device to manage central sleep apnea in heart failure patients, reducing mortality rise and improving quality of life.

A subgroup analysis of the SELECT trial confirmed semaglutide 2.4 mg benefits patients with heart failure across ejection fraction spectra, improving MACE and heart failure outcomes.

Cascade testing strategies significantly increased the detection of FH, with direct contact yielding a 16-fold higher testing rate, according to the IMPACT-FH study.

Laurence Sperling, MD, offers perspective on multiple topics within the evolving field of lipid management and dyslipidemia.

In this episode, hosts react to the announced CMS list prices for the first 10 drugs chosen for negotiation as part of the Inflation Reduction Act.

On August 19, 2024, Liquidia Corporation announced the FDA's tentative approval of treprostinil inhalation powder for adults with PAH and PH-ILD.

A recent study found that noise exposure of power looms (≥ 85 decibels) puts workers at risk of their overall blood pressure increasing.

HIIT exercise post-stroke improved aerobic fitness more than MICT, with significant gains in peak VO2 after 12 weeks.

Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.

New study suggests MRI-derived pressure measurements indicate a 5-fold increase in heart failure risk.

Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.

Maintaining stable HbA1c levels in target ranges reduces Alzheimer Disease risk in older adults with diabetes, emphasizing the importance of personalized glycemic control.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

In this episode, hosts are joined by Muthiah Vaduganathan, MD, MPH, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials.

On August 05, 2024, less than a month prior to its presentation at ESC 24, Bayter has announced topline data from the FINEARTS-HF trial indicating finerenone met the primary endpoint.

The July 2024 cardiology month in review spotlights new data from obicetrapib, a deep dive into risk stratification algorithms, and studies on the need for optimal care.

Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.

New research found high diastolic blood pressure is linked to greater odds of a female having a migraine. The study found no other associations between migraines and other CVD factors.

A study cautions the AHA's new PREVENT equations may underprescribe statins and antihypertensives, potentially causing 107,000 more ASCVD events in 10 years.

The phase 3 trial suggest obicetrapib offered significant reductions in LDL-C when added to maximally tolerated lipid-lowering therapy in HeFH.

A study found wearable devices alerting irregular heart rhythms amplified anxiety in 1 in 5 participants with atrial fibrillation, which led people to be more likely to seek care.

Personalized text messages can boost physical activity in cardiac rehab patients, especially in early stages, but effectiveness varies by time and device, study finds.

UAB research shows AHA’s Life’s Essential 8 and Simple 7 scores aid public health but are less effective than pooled cohort equations for predicting individual cardiovascular risk.

Despite recommendations, an analysis of more than 3.2 million youths suggests fewer than 15% of children/adolescents receive lipid screening.